95 related articles for article (PubMed ID: 12672069)
1. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells.
Karagiannis SN; Wang Q; East N; Burke F; Riffard S; Bracher MG; Thompson RG; Durham SR; Schwartz LB; Balkwill FR; Gould HJ
Eur J Immunol; 2003 Apr; 33(4):1030-40. PubMed ID: 12672069
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers.
Suzuki M; Kato-Nakano M; Kawamoto S; Furuya A; Abe Y; Misaka H; Kimoto N; Nakamura K; Ohta S; Ando H
Cancer Sci; 2009 Sep; 100(9):1623-30. PubMed ID: 19555390
[TBL] [Abstract][Full Text] [Related]
3. IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells.
Karagiannis SN; Bracher MG; Hunt J; McCloskey N; Beavil RL; Beavil AJ; Fear DJ; Thompson RG; East N; Burke F; Moore RJ; Dombrowicz DD; Balkwill FR; Gould HJ
J Immunol; 2007 Sep; 179(5):2832-43. PubMed ID: 17709497
[TBL] [Abstract][Full Text] [Related]
4. Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application.
Karagiannis SN; Josephs DH; Karagiannis P; Gilbert AE; Saul L; Rudman SM; Dodev T; Koers A; Blower PJ; Corrigan C; Beavil AJ; Spicer JF; Nestle FO; Gould HJ
Cancer Immunol Immunother; 2012 Sep; 61(9):1547-64. PubMed ID: 22139135
[TBL] [Abstract][Full Text] [Related]
5. Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling.
Josephs DH; Bax HJ; Dodev T; Georgouli M; Nakamura M; Pellizzari G; Saul L; Karagiannis P; Cheung A; Herraiz C; Ilieva KM; Correa I; Fittall M; Crescioli S; Gazinska P; Woodman N; Mele S; Chiaruttini G; Gilbert AE; Koers A; Bracher M; Selkirk C; Lentfer H; Barton C; Lever E; Muirhead G; Tsoka S; Canevari S; Figini M; Montes A; Downes N; Dombrowicz D; Corrigan CJ; Beavil AJ; Nestle FO; Jones PS; Gould HJ; Sanz-Moreno V; Blower PJ; Spicer JF; Karagiannis SN
Cancer Res; 2017 Mar; 77(5):1127-1141. PubMed ID: 28096174
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic IgE Antibodies: Harnessing a Macrophage-Mediated Immune Surveillance Mechanism against Cancer.
Karagiannis SN; Josephs DH; Bax HJ; Spicer JF
Cancer Res; 2017 Jun; 77(11):2779-2783. PubMed ID: 28526770
[TBL] [Abstract][Full Text] [Related]
7. Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells.
Karagiannis SN; Bracher MG; Beavil RL; Beavil AJ; Hunt J; McCloskey N; Thompson RG; East N; Burke F; Sutton BJ; Dombrowicz D; Balkwill FR; Gould HJ
Cancer Immunol Immunother; 2008 Feb; 57(2):247-63. PubMed ID: 17657488
[TBL] [Abstract][Full Text] [Related]
8. Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity.
Rudman SM; Josephs DH; Cambrook H; Karagiannis P; Gilbert AE; Dodev T; Hunt J; Koers A; Montes A; Taams L; Canevari S; Figini M; Blower PJ; Beavil AJ; Nicodemus CF; Corrigan C; Kaye SB; Nestle FO; Gould HJ; Spicer JF; Karagiannis SN
Clin Exp Allergy; 2011 Oct; 41(10):1400-13. PubMed ID: 21569129
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells.
Karagiannis P; Singer J; Hunt J; Gan SK; Rudman SM; Mechtcheriakova D; Knittelfelder R; Daniels TR; Hobson PS; Beavil AJ; Spicer J; Nestle FO; Penichet ML; Gould HJ; Jensen-Jarolim E; Karagiannis SN
Cancer Immunol Immunother; 2009 Jun; 58(6):915-30. PubMed ID: 18941743
[TBL] [Abstract][Full Text] [Related]
10. Epithelial damage and tissue γδ T cells promote a unique tumor-protective IgE response.
Crawford G; Hayes MD; Seoane RC; Ward S; Dalessandri T; Lai C; Healy E; Kipling D; Proby C; Moyes C; Green K; Best K; Haniffa M; Botto M; Dunn-Walters D; Strid J
Nat Immunol; 2018 Aug; 19(8):859-870. PubMed ID: 30013146
[TBL] [Abstract][Full Text] [Related]
11. An immunologically relevant rodent model demonstrates safety of therapy using a tumour-specific IgE.
Josephs DH; Nakamura M; Bax HJ; Dodev TS; Muirhead G; Saul L; Karagiannis P; Ilieva KM; Crescioli S; Gazinska P; Woodman N; Lombardelli C; Kareemaghay S; Selkirk C; Lentfer H; Barton C; Canevari S; Figini M; Downes N; Dombrowicz D; Corrigan CJ; Nestle FO; Jones PS; Gould HJ; Blower PJ; Tsoka S; Spicer JF; Karagiannis SN
Allergy; 2018 Dec; 73(12):2328-2341. PubMed ID: 29654623
[TBL] [Abstract][Full Text] [Related]
12. IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states.
Pellizzari G; Hoskin C; Crescioli S; Mele S; Gotovina J; Chiaruttini G; Bianchini R; Ilieva K; Bax HJ; Papa S; Lacy KE; Jensen-Jarolim E; Tsoka S; Josephs DH; Spicer JF; Karagiannis SN
EBioMedicine; 2019 May; 43():67-81. PubMed ID: 30956175
[TBL] [Abstract][Full Text] [Related]
13. IgE Antibodies: From Structure to Function and Clinical Translation.
Sutton BJ; Davies AM; Bax HJ; Karagiannis SN
Antibodies (Basel); 2019 Feb; 8(1):. PubMed ID: 31544825
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2.
Pellizzari G; Martinez O; Crescioli S; Page R; Di Meo A; Mele S; Chiaruttini G; Hoinka J; Batruch I; Prassas I; Grandits M; López-Abente J; Bugallo-Blanco E; Ward M; Bax HJ; French E; Cheung A; Lombardi S; Figini M; Lacy KE; Diamandis EP; Josephs DH; Spicer J; Papa S; Karagiannis SN
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34112739
[TBL] [Abstract][Full Text] [Related]
15. IgE immunotherapy: a novel concept with promise for the treatment of cancer.
Josephs DH; Spicer JF; Karagiannis P; Gould HJ; Karagiannis SN
MAbs; 2014; 6(1):54-72. PubMed ID: 24423620
[TBL] [Abstract][Full Text] [Related]
16. A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy.
Daniels-Wells TR; Helguera G; Leuchter RK; Quintero R; Kozman M; Rodríguez JA; Ortiz-Sánchez E; Martínez-Maza O; Schultes BC; Nicodemus CF; Penichet ML
BMC Cancer; 2013 Apr; 13():195. PubMed ID: 23594731
[TBL] [Abstract][Full Text] [Related]
17. Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial.
Spicer J; Basu B; Montes A; Banerji U; Kristeleit R; Miller R; Veal GJ; Corrigan CJ; Till SJ; Figini M; Canevari S; Barton C; Jones P; Mellor S; Carroll S; Selkirk C; Nintos G; Kwatra V; Funingana IG; Doherty G; Gould HJ; Pellizzari G; Nakamura M; Ilieva KM; Khiabany A; Stavraka C; Chauhan J; Gillett C; Pinder S; Bax HJ; Josephs DH; Karagiannis SN
Nat Commun; 2023 Jul; 14(1):4180. PubMed ID: 37491373
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
